Abstract:Background: Percutaneous coronary interventions to implant bioresorbable vascular scaffolds (BVSs) were designed to reduce the late thrombotic events that occur with metallic stents.Purpose: To estimate the incidence of scaffold thrombosis after BVS implantation and compare everolimus-eluting BVSs with everolimus-eluting metallic stents (EESs) in terms of safety and efficacy at mid-and long-term follow-up in adults who had a percutaneous coronary intervention.Data Sources: PubMed, EMBASE, the Cochrane Library, conference proceedings, and relevant Web sites from inception until 20 May 2017, without language restriction.Study Selection: 7 randomized trials and 38 observational studies (each with a minimum of 6 months and 100 patient-years of follow-up) in adults with coronary artery disease who had a BVS or an EES and reported scaffold or stent thrombosis (main outcome) or other secondary outcomes (such as death, myocardial infarction, or revascularization).Data Extraction: 2 reviewers independently extracted study data, rated study quality, and assessed strength of evidence.Data Synthesis: The pooled incidence of definite or probable scaffold thrombosis after BVS implantation was 1.8% (95% CI, 1.5% to 2.2%) at a median follow-up of 1 year (41 studies, 21 884 patients) and 0.8% (CI, 0.5% to 1.3%) beyond 1 year (14 studies, 4688 patients). Seven trials involving 5578 patients that directly compared BVSs with EESs showed an increased risk for definite or probable scaffold thrombosis (odds ratio [OR], 3.40 [CI, 2.01 to 5.76]) with BVSs at a median follow-up of 25 months. Increased risks were present at early (prominently subacute), late, and very late stages, and odds beyond 1 year were almost double those seen within 1 year. Bioresorbably vascular scaffolds increased risks for myocardial infarction (OR, 1.63 [CI, 1.26 to 2.10]), target lesion revascularization (OR, 1.31 [CI, 1.03 to 1.67]), and target lesion failure (OR, 1.37 [CI, 1.12 to 1.66]); the odds for these 3 end points also increased over time. The incidences of all-cause, cardiac, and noncardiac death and of target vessel and any revascularization did not differ.Limitation: Quality of observational studies was unclear, and some data were unpublished.Conclusion: Compared with EESs, BVSs increased the risks for scaffold thrombosis and other thrombotic events at mid-and long-term follow-up, and risks increased over time.

Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis

Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

Mid-term Outcomes of Bioresorbable Vascular Scaffolds Vs Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndromes

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis.

Efficacy and safety of bioresorbable scaffolds in patients with coronary bifurcation lesions: A systematic review and meta-analysis

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents Versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting

Bio-resorbable polymer stents: a review of material progress and prospects

Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

The efficacy and safety of bioresorbable bascular scaffolds in percutaneous coronary intervention: a meta-analysis

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry

Three-year Clinical Outcomes of a Sirolimus-Eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis.

Long-term outcomes of drug-eluting versus bare-metal stent for ST-elevation myocardial infarction.

Meta-analysis of long-term outcomes of drug-eluting stent implantations for chronic total coronary occlusions.

Mid- And Long-Term Outcome Comparisons Of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents A Systematic Review And Meta-Analysis

Final Report of the 5-Year Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold in the Treatment of Single De Novo Coronary Lesions in a First-in-human Study